22 April 2018

TIKOMED IS INTERVIEWED AT BIOSPRING ABOUT IBSOLVMIR FOR IMPROVED CELL-THERAPIES BY MIKE WARD

TikoMeds promising Phase 2 project for more efficient cell-therapies was presented at BioEurope Spring in Amsterdam. Below follows an interview by Mike Ward of Adam Bruce, Founder and CEO of TikoMed.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More
5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
SEE MORE